| Company Name: |
OPULENT PHARMA
|
| Tel: |
+91-9106692785 +91-9106692785 |
| Email: |
info@opulentpharma.com |
| Products Intro: |
Product Name:4-Hydroxy Atorvastatin
CAS:265989-44-4
Purity:98% Package:1 kg,5 kg, 10 kg,25kg and 1 MT
|
|
| | para-Hydroxy Atorvastatin CalciuM Salt Basic information |
| Product Name: | para-Hydroxy Atorvastatin CalciuM Salt | | Synonyms: | 4-Hydroxy Atorvastatin HeMicalciuM Salt;4-Hydroxy Atorvastatin;Atorvastatin impurity 35/para-Hydroxy Atorvastatin Calcium Salt/(3R,5R)-7-[2-(4-fluorophenyl)-4-[(4-hydroxyphenyl)carbamoyl]-3-phenyl-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Calcium Salt;Atorvastatin Impurity 52;Atorvastatin Impurity J;Para-Hydroxy Atorvastatin Calcium;Atorvastatin Impurity 154;calcium,(3S,5S)-7-[2-(4-fluorophenyl)-4-[(4-hydroxyphenyl)carbamoyl]-3-phenyl-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate | | CAS: | 265989-44-4 | | MF: | C66H70CaF2N4O12 | | MW: | 1189.3564064 | | EINECS: | | | Product Categories: | | | Mol File: | 265989-44-4.mol |  |
| | para-Hydroxy Atorvastatin CalciuM Salt Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 25 mg/ml; DMF:PBS (pH 7.2) (1:9): 0.1 mg/ml; DMSO: 15 mg/ml; Ethanol: 0.5 mg/ml | | form | A crystalline solid |
| | para-Hydroxy Atorvastatin CalciuM Salt Usage And Synthesis |
| Description | 4-hydroxy Atorvastatin is a metabolite of atorvastatin , an HMG-CoA reductase inhibitor present in formulations that have been used to treat hypercholesterolemia and certain dyslipidemias.1,2,3,4 Atorvastatin is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 to form 4-hydroxy atorvastatin.1 | | References | 1. Hong, J.H., Youm, J.K., Kwon, M.J., et al. K6PC-5, a direct activator of sphingosine kinase 1, promotes epidermal differentiation through intracellular Ca2+ signaling J. Invest. Dermatol. 128,2166-2178(2008).
2. Dart, A., Jerums, G., Nicholson, G., et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia Am. J. Cardiol. 80(1),39-44(1997).
3. Group, T.D.A.L.I.S. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI study: A double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia Diabetes Care 24(8),1335-1341(2001).
4. van Dam, M., Zwart, M., de Beer, F., et al. Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia Heart 88(3),234-238(2002). |
| | para-Hydroxy Atorvastatin CalciuM Salt Preparation Products And Raw materials |
|